Margaux J. Hall
Margaux Hall is a partner in the firm’s nationally recognized health care practice. Margaux is a leading lawyer in drug pricing, managed care and value-based payment arrangements. She brings to clients an understanding of the transformative legal and policy issues affecting pharmaceutical manufacturers, and the life sciences and health care sectors more broadly.
Named a Law360 “Rising Star” for health care in 2019, Margaux provides sophisticated regulatory and strategic business counsel to clients on matters involving innovative contracting arrangements; drug price reporting obligations under the Medicaid, Medicare, and the Public Health Service programs, as well as state drug price transparency laws; and vertical integrations and other transactions related to the pharmaceutical supply chain. She also provides sophisticated regulatory and business strategy advice to national and regional health insurers who manage prescription drug benefits in compliance with Medicare Advantage, Medicare Part D and Medicaid managed care program requirements.
Margaux’s deep knowledge of the pharmaceutical supply chain also is invaluable in major transactions involving vertical integrations in, or other fundamental changes to, the supply chain. Investors and others turn to Margaux to assist them in assessing and evaluating their investments in the health care and life sciences sectors.
Margaux has dedicated her career to understanding health care in the U.S. and worldwide; after graduating from Harvard Law School, she pursued a Fulbright Fellowship to research health care law and health system reform in South Africa and then led similar research programs at the World Bank. Margaux also completed a post-graduate fellowship focusing on health law through Columbia Law School.
Margaux also has developed a robust practice with pro bono clients in the health care arena. As part of this, she has long represented Capital Clubhouse, a nonprofit organization serving people living with mental illness, during its creation of a community health center.
- Co-author, “Rutledge vs. PCMA: The future of state regulation of pharmacy benefit,” Westlaw Today (June 25, 2021)
- Co-author, “Potential Costs of Reshoring Pharmaceutical Manufacturing,” Bloomberg Law (April 7, 2021)
- Co-author, “Federal Gov't Can Learn From State Drug Pricing Efforts,” Law360 (March 23, 2021)
- Co-author, “Pharma & Med Device Bidding, State-Mandated Disclosures, & Public Records Laws,” Bloomberg Law (March 2, 2021)
- Author, “3 Drug Pricing Strategy Considerations Under Biden Admin.,” Law360 (February 16, 2021)
- Quoted, “Anthem, CareFirst Confront the High Cost of Specialty Drugs,” Financial Times Health Payer Specialist (January 29, 2021)
- Cited, “Hire Up: Big Firms Build Up in DC, Add Bankruptcy and Benefits Partners Elsewhere,” The American Lawyer (October 16, 2020)
- Cited, “Industry Moves” Thomson Reuters’ Westlaw Today (October 15, 2020)
- Profiled, “Ropes & Gray Nabs Health Partner From Hogan Lovells,” Law360 (October 15, 2020)
- Program Chair, “Drug Pricing 2021: An Overview and the Evolving Legal and Policy Landscape,” Practising Law Institute Webcast (September 20, 2021)
- Speaker, “Outlook 2021: Washington, D.C. Updates and Insights on Life Sciences and Health Care,” Ropes & Gray Teleconference (February 25, 2021)
- Panelist, “From the Boardroom: An Industry Insider’s Latest View of the Life Sciences & Healthcare Industry in a Post-Covid World,” Ropes & Gray Virtual Event (January 10, 2021)
- JD, cum laude, Harvard Law School, 2008; Managing Editor of the Harvard Journal of Law & Technology
- BS (Management Science & Engineering, and honors in Civil Engineering), with distinction, Stanford University, 2003; Phi Beta Kappa
Admissions / Qualifications
- District of Columbia, 2016
- New York, 2009
- Law360 Rising Star (2019)
- Fellow, Columbia Law School, focus on health care law (2012-2014)
- Fulbright Scholar, South Africa (2008-2009)